The groundbreaking clinical trial of GDNF, a potential treatment for Parkinson's, is now complete. Analysis of the results is now well underway and is expected to be published in the coming months.

New research shows promise for repurposed drugs that slow dementia.

New research published in Nature Biotechnology shows that it may be possible to reprogramme cells inside the brain to reverse the symptoms of Parkinson's.

Research suggests there may be a link between hepatitis infection and an increased risk of developing Parkinson's.

We’re excited to announce that Professor David Dexter has joined us as our new Deputy Director of Research.

Parkinson's UK and the University of Sheffield have launched a new £1million virtual biotech company, Keapstone Therapeutics, to combine world-leading research from the University with funding and expertise from the charity to develop new treatments.

US researchers have announced the launch of a Phase II clinical trial of the cancer drug nilotinib in people with Parkinson’s.

Results from a clinical trial suggest an inhalable form of levodopa could help people with Parkinson's who experience 'off periods'.

Researchers have discovered a potential way to tell the difference between people with Parkinson's and those with parkinsonisms using a simple blood test.

Researchers in Oxford have developed a unique way to identify existing drugs that could potentially be repurposed for treating Parkinson’s.